Follow
Alana S. Weinstein
Title
Cited by
Cited by
Year
Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study
R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ...
Journal of Clinical Oncology 36 (24), 2492, 2018
5902018
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
JJ Alumkal, D Sun, E Lu, TM Beer, GV Thomas, E Latour, R Aggarwal, ...
Proceedings of the National Academy of Sciences 117 (22), 12315-12323, 2020
982020
TumorMap: exploring the molecular similarities of cancer samples in an interactive portal
Y Newton, AM Novak, T Swatloski, DC McColl, S Chopra, K Graim, ...
Cancer research 77 (21), e111-e114, 2017
772017
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer
R Aggarwal, GR Romero, V Friedl, A Weinstein, A Foye, J Huang, F Feng, ...
Prostate cancer and prostatic diseases 24 (1), 81-87, 2021
172021
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
TC Westbrook, X Guan, E Rodansky, D Flores, CJ Liu, AM Udager, ...
Nature communications 13 (1), 5345, 2022
162022
Copy number loss of 17q22 is associated with enzalutamide resistance and poor prognosis in metastatic castration-resistant prostate cancer
X Guan, D Sun, E Lu, JA Urrutia, RE Reiter, M Rettig, CP Evans, P Lara Jr, ...
Clinical Cancer Research 26 (17), 4616-4624, 2020
102020
The genomic and epigenomic landscape of double-negative metastatic prostate cancer
A Lundberg, M Zhang, R Aggarwal, H Li, L Zhang, A Foye, M Sjöström, ...
Cancer Research 83 (16), 2763-2774, 2023
72023
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer
DH Kwon, L Zhang, DA Quigley, A Foye, WS Chen, CK Wong, FY Feng, ...
Urologic Oncology: Seminars and Original Investigations 38 (12), 931. e9-931 …, 2020
72020
Using transcriptional signatures to find cancer drivers with LURE
D Haan, R Tao, V Friedl, IN Anastopoulos, CK Wong, AS Weinstein, ...
Pacific Symposium on Biocomputing 2020, 343-354, 2019
72019
Hydra: A mixture modeling framework for subtyping pediatric cancer cohorts using multimodal gene expression signatures
J Pfeil, LM Sanders, I Anastopoulos, AG Lyle, AS Weinstein, Y Xue, ...
PLoS computational biology 16 (4), e1007753, 2020
42020
Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell …
EJ Small, RR Aggarwal, V Friedl, A Weinstein, GV Thomas, LD True, ...
Journal of Clinical Oncology 38 (6_suppl), 158-158, 2020
32020
Abstract LB196: An atlas of accessible chromatin in advanced prostate cancer
R Shrestha, LN Chesner, M Zhang, S Zhou, A Foye, A Lundberg, ...
Cancer Research 84 (7_Supplement), LB196-LB196, 2024
2024
Abstract B012: Genomic and epigenomic drivers of double-negative metastatic prostate cancer
A Lundberg, M Zhang, RR Aggarwal, H Li, L Zhang, A Foye, M Sjöström, ...
Cancer Research 83 (11_Supplement), B012-B012, 2023
2023
Abstract A029: Whole genome and transcriptome analysis of paired metastatic biopsies identified resistance mechanisms in castration-resistant prostate cancer
X Zhu, D Vis, M Sjöström, R Shrestha, J Kneppers, T Severson, Y Zhu, ...
Cancer Research 83 (11_Supplement), A029-A029, 2023
2023
Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
I de Kouchkovsky, L Zhang, J Huang, K Trepka, J Chou, A Foye, D Shui, ...
Journal of Clinical Oncology 40 (6_suppl), 167-167, 2022
2022
ADRB2 expression in progressive metastatic castration-resistant prostate cancer.
D Kwon, L Zhang, A Foye, WS Chen, FY Feng, A Bailey, J Huang, ...
Journal of Clinical Oncology 38 (6_suppl), 145-145, 2020
2020
Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC).
G Rubio Romero, A Weinstein, V Friedl, A Foye, D Playdle, A Sabol, P Li, ...
Journal of Clinical Oncology 37 (15_suppl), 5051-5051, 2019
2019
DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate …
RR Aggarwal, P Lloyd, J Huang, TM Beer, L Zhang, GV Thomas, LD True, ...
Journal of Clinical Oncology 36 (15_suppl), 5039-5039, 2018
2018
LURE PSB Supplemental Methods
D Haan, R Tao, V Friedl, IN Anastopoulos, CK Wong, AS Weinstein, ...
The system can't perform the operation now. Try again later.
Articles 1–19